Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArkemaARKAF 71 Equity-to-Asset is 0.48 as of Jun. 2026, which is 2% below its 10-year median of 0.49. GuruFocus rates ARKAF with a GF Score™ of 71/100 and a GF Value™ of $88.35 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 1,615 Chemicals companies, Arkema ranks worse than 66.75% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Arkema's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $7,811 Mil. Arkema's Total Assets for the quarter that ended in Jun. 2026 was $16,328 Mil.
Therefore, Arkema's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.48.
The historical rank and industry rank for Arkema's Equity-to-Asset or its related term are showing as below:
ARKAF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43 Med: 0.49 Max: 0.55
Current: 0.48
During the past 13 years, the highest Equity to Asset Ratio of Arkema was 0.55. The lowest was 0.43. And the median was 0.49.
ARKAF's Equity-to-Asset is ranked worse than 66.75% of 1615
companies
in the Chemicals industry
Industry Median: 0.6
vs ARKAF: 0.48
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Arkema Equity-to-Asset Related Terms
Arkema Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Arkema's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARKAF vs LIN, SHW, ECL: Equity-to-Asset Comparison
For the Specialty Chemicals subindustry, Arkema's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arkema Equity-to-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Arkema's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Arkema's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Arkema's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arkema (ARKAF) has a Equity-to-Asset of 0.48 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arkema and its competitors. This is near median its historical median of 0.49. Over the past decade, Arkema's Equity-to-Asset has ranged from 0.43 to 0.55. According to the industry distribution chart, Arkema ranks #1078 out of 1615 companies in the Chemicals industry, placing it in the top 66.7%.
Is Arkema's Equity-to-Asset too high?
Arkema's current Equity-to-Asset of 0.48 is near median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.55. The Chemicals industry median Equity-to-Asset is 0.60. Arkema's value of 0.48 is 20% below this industry median. Based on the distribution chart, Arkema ranks #1078 out of 1615 companies in the Chemicals industry, which is below the industry midpoint. Overall, Arkema has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arkema's Equity-to-Asset compare to LIN and SHW?
According to the Chemicals industry distribution chart, Arkema ranks #1078 out of 1615 companies for Equity-to-Asset. This places Arkema in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Arkema's value of 0.48 is 20% below this benchmark. Historically, Arkema's own Equity-to-Asset has ranged from 0.43 to 0.55 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.60, Arkema has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Chemicals company?
The median Equity-to-Asset among Chemicals companies is 0.60, based on 1,615 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arkema's current Equity-to-Asset of 0.48 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arkema and its competitors. For the Chemicals industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arkema's current Equity-to-Asset is 0.48, which is near median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arkema stock overvalued right now?
Based on GuruFocus' analysis, Arkema (ARKAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $88.35, compared to a current price of $68.44 — trading 22.5% below its estimated fair value. The current Equity-to-Asset is 0.48, which is near median its 10-year median of 0.49 and 20% below the Chemicals industry median of 0.60. Arkema's overall GF Score™ is 71/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Arkema (ARKAF), the current Equity-to-Asset is 0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arkema (ARKAF) Overvalued in 2026?
Based on GuruFocus' analysis, Arkema stock appears to be undervalued.
The current stock price of $68.44 is trading 22.5% below its estimated GF Value™ of $88.35.
GuruFocus considers Arkema to be Modestly Undervalued.
Key valuation signals for ARKAF:
Equity-to-Asset: 0.48 (near median its 10-year median of 0.49)
GF Value™: $88.35 vs. price of $68.44 (22.5% below fair value)
Industry Position: 20% below the Chemicals median (#1078 of 1615)
No single metric tells the full story. See the ARKAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arkema SA operates in the specialty materials industry, offering adhesives, acrylics, technical fluids, chemicals, additives, and other materials that are used in various industries globally. Along with its subsidiaries, it operates in the following segments: Adhesive Solutions, Advanced Materials, Intermediates, and Coating Solutions. Maximum revenue is generated from the Advanced Materials segment, which offers high-performance polymers, like specialty polyamides, PVDF, polyimides, fluorospecialties, and PEKK; and performance additives, covering interface agents, organic peroxides, thiochemicals, and hydrogen peroxide. Geographically, the Group generates maximum revenue from North America, followed by Europe, Asia, and the Rest of the world.
71GF Score
Get the complete analysis for ARKAF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARKAF has been successfully added to your 
